Arcutis Biotherapeutics, a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement process. The filing, which is a standard requirement under Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for additional proxy solicitation. This filing was made by the registrant, Arcutis Biotherapeutics, Inc., and does not require an additional filing fee. The definitive additional materials suggest that Arcutis is preparing for upcoming corporate actions that may require shareholder votes, although the specific resolutions or proposals were not detailed in the announcement.

Arcutis Biotherapeutics, a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement process. The filing, which is a standard requirement under Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for additional proxy solicitation. This filing was made by the registrant, Arcutis Biotherapeutics, Inc., and does not require an additional filing fee. The definitive additional materials suggest that Arcutis is preparing for upcoming corporate actions that may require shareholder votes, although the specific resolutions or proposals were not detailed in the announcement.